Vitor tablets

Dexa Medica

Ingredients in every tablet

Pitavastatin 2 mg

Each package contains

3 blisters of 10 tablets

Other details

Dosage form:Tablet; coated
Flavour: None

W.H.O. classification

ATC Level 1: C - Cardiovascular system
ATC Level 2: C10 - Lipid Modifying Agents
ATC Level 3: C10A - Lipid Modifying Agents; Plain



NOT SAFEThis item is not safe for use during pregnancy.


NOT SAFEThis item is not safe for use during lactation.


CAUTIONThis item may not be safe for use with alcohol. Use with caution.


CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution.

Available in


Dosage information

The dose range for pitavastatin is 1 to 4 mg orally once daily at any time of the day with or without food. The recommended starting dose is 2 mg and the maximum dose is 4 mg. The starting dose and maintenance doses of pitavastatin should be individualized according to patient characteristics, such as goal of therapy and response. After initiation or upon titration of pitavastatin, lipid levels should be analyzed after 4 weeks and the dosage adjusted accordingly.

Patients with moderate and severe renal impairment (glomerular filtration rate 30 – 59 ml/minute/1.73 m2 and 15 – 29 ml/minute/1.73 m2 not receiving hemodialysis, respectively) as well as end-stage renal disease receiving hemodialysis should receive a starting dose of pitavastatin 1 mg once daily and a maximum dose of pitavastatin 2 mg once daily.

In patients taking erythromycin, a dose of pitavastatin 1 mg once daily should not be exceeded.

In patients taking rifampin, a dose of pitavastatin 2 mg once daily should not be exceeded.


Drug therapy should be one component of multiple-risk-factor intervention in individuals who require modifications of their lipid profile. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol only when the response to diet and other nonpharmacological measures has been inadequate.

1. Primary hyperlipidemia and mixed dyslipidemia
Pitavastatin is indicated as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase HDL-C in Adults patients with primary hyperlipidemia or mixed dyslipidemia.

2. Limitations of use
Doses of pitavastatin greater than 4 mg once daily were associated with an increased risk for severe myopathy in premarketing clinical studies. Do not exceed 4 mg once daily dosing of pitavastatin.
The effect of pitavastatin on cardiovascular morbidity and mortality has not been determined.
Pitavastatin has not been studied in Fredrickson Type I, III, and V dyslipidemias.


The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.